PROCEPT BioRobotics

PROCEPT BioRobotics is a surgical robotics company based in San Jose, California, specializing in urology. Founded in 2007, the company focuses on developing minimally invasive robotic solutions for benign prostatic hyperplasia (BPH). It went public on NASDAQ in September 2021 under the ticker PRCT. With a team of 756 employees, PROCEPT operates internationally, aiming to enhance BPH treatment through advanced robotic systems. The company's key products include the AquaBeam® Robotic System, which utilizes real-time ultrasound imaging for precise tissue targeting, and the HYDROS Robotic System, designed for Aquablation® therapy that employs a high-velocity waterjet for tissue removal. Aquablation® therapy is clinically proven to provide effective symptom relief for BPH patients while preserving sexual function and continence. PROCEPT primarily serves urologists and hospitals, emphasizing partnerships with healthcare providers to improve patient outcomes.